Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Henit YanaiAnna KagramanovaOleg KnyazevJoão SabinoShana HaenenGerassimos J MantzarisKaterina MountakiAlessandro ArmuzziDaniela PuglieseFederica FurfaroGionata FiorinoDavid DrobneTina KurentSharif YassinNitsan MaharshakFabiana CastiglioneRoberto de SireOlga Maria NardoneKlaudia FarkasTamás ResálZeljko KrznaricMarko BrinarElena ChashkovaMoran Livne MargolinUri KopylovCristina BezzioAriella Bar-Gil ShitritMilan LukasMaria ChaparroMarie TruyensStéphane NanceyTriana LobatonJavier P GisbertSimone SaibeniPéter BacsúrPeter BossuytJulien SchulbergFrank HoentjenChiara ViganòAndrea PalermoJoanna TorresJoana RevésKonstantinos KarmirisMagdalini VelegrakiEdoardo SavarinoPanagiotis MarkopoulosEftychia TsironiPierre EllulCristina Calviño SuárezRoni WeisshofDana Ben-HurTimna NaftaliCarl ErikssonIoannis E KoutroubakisKalliopi FoteinogiannopoulouJimmy K LimdiEleanor LiuGerard SurísEmma CalabreseFrancesca ZorziRafał FilipDavide Giuseppe RibaldoneYifat SnirIdan GorenHagar Banai-EranYelena BroytmanHadar Amir BarakIrit Avni BironJacob E OllechIris DotanMaya Aharoni GolanPublished in: Journal of Crohn's & colitis (2022)
Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups.